Collectively, our findings provide a new mechanism by which AGR2 might act as an upstream factor of XBP1 to modulate ER homeostasis and influence the cell death or survival status in sorafenib-sensitive and sorafenib-resistant HCC. Here, AGR2 is linked to hepatocellular carcinoma.